While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent trial. The study enhances Lilly's position in the obesity drug market, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Billy and Tina, the last two Asian elephants at the Los Angeles Zoo, were set to be moved to a new location at the Tulsa Zoo, ...

The Canadian Medical Association (CMA) congratulates Canada's Minister of Health Marjorie Michel and the entire new federal cabinet on their appointments today. The CMA is eager to collaborate with ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible ...